- Conditions
- Endometriosis
- Interventions
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
- Drug
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Norwalk, California • Greenwood Village, Colorado + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Endometriosis
- Interventions
- elagolix, estradiol/norethindrone acetate (E2/NETA)
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 37
- States / cities
- Anniston, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more
- Conditions
- Endometriosis
- Interventions
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
- Drug
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 486 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Chiefland, Florida + 19 more
- Conditions
- Endometriosis
- Interventions
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo capsule to match Add-back capsule
- Drug
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 356 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 8
- States / cities
- Dothan, Alabama • Homestead, Florida • Tampa, Florida + 5 more
- Conditions
- Endometriosis
- Interventions
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
- Drug
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 79 more
- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroid
- Interventions
- Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 388 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 76
- States / cities
- Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more